Erika Van Landuyt Selected Research

cobicistat mixture with darunavir

1/2019	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
1/2019	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
1/2018	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erika Van Landuyt Research Topics

Disease

3	Infections 01/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

3	cobicistat mixture with darunavirIBA 01/2019 - 01/2018
3	TabletsIBA 01/2019 - 01/2018
2	emtricitabine tenofovir alafenamideIBA 01/2019 - 01/2019
1	tenofovir alafenamideIBA 01/2018
1	Emtricitabine (Emtriva)FDA Link 01/2018